Abstract

Case Report

Metabolic syndrome: A case report

Dragan Klaric, Marta Martinis* and Marta Klaric

Published: 08 September, 2021 | Volume 5 - Issue 1 | Pages: 031-035

Metabolic syndrome composed of abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance and/or glucose intolerance, proinflammatory state and prothrombotic state is a complex multisystem disorder. It is well known that patients with metabolic syndrome have increased cardiovascular risk and risk of developing diabetes type II. But besides these well known risk states, there are other conditions such as polycystic ovary syndrome, fatty liver, cholesterol gallstones, asthma, sleep disturbances and some forms of cancer associated with a metabolic syndrome. In this case report we will present a patient who developed many of these conditions related to the metabolic syndrome and will highlight the novel efforts regarding to the lifestyle changes, primarily weight loss.

Read Full Article HTML DOI: 10.29328/journal.acem.1001022 Cite this Article Read Full Article PDF

Keywords:

9244747344

References

  1. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr.2007; 86: 836-842. PubMed: https://pubmed.ncbi.nlm.nih.gov/18265477/
  2. Grundy SMBrewer HB JrCleeman JI, Smith Jr SC, Lenfant C, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004; 24: 13-18. PubMed: https://pubmed.ncbi.nlm.nih.gov/14766739/
  3. Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017; 11: 215-225. PubMed: https://pubmed.ncbi.nlm.nih.gov/28639538/
  4. Gami ASWitt BJHoward DE, Erwin PJ, Gami LA, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol.2007; 49: 403-414. PubMed: https://pubmed.ncbi.nlm.nih.gov/17258085/
  5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23: 469-480. PubMed: https://pubmed.ncbi.nlm.nih.gov/16681555/
  6. Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med (Lond) 2018; 79: 694-699. PubMed: https://pubmed.ncbi.nlm.nih.gov/30526098/
  7. Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, et al. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel) 2020; 10: 940. PubMed: https://pubmed.ncbi.nlm.nih.gov/33198092/
  8. Mikolasevic IMilic STurk Wensveen T, Grgic I, Jakopcic V, et al. Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol. 2016; 22: 9488-9505. PubMed: https://pubmed.ncbi.nlm.nih.gov/27920470/ 
  9. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016; 22: 4079-4090. PubMed: https://pubmed.ncbi.nlm.nih.gov/27122660/
  10. Younossi Z, Tacke F, Arrese M, Sharma BC, Mostafa I, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2018; 69: 2672-2682. PubMed: https://pubmed.ncbi.nlm.nih.gov/30179269/
  11. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019; 7: 313-324. PubMed: https://pubmed.ncbi.nlm.nih.gov/30174213/
  12. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015; 62: 47–64. PubMed: https://pubmed.ncbi.nlm.nih.gov/25920090/
  13. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363: 1341-1350. PubMed: https://pubmed.ncbi.nlm.nih.gov/20879883/
  14. Han E, Lee YH, Kim YD, Kim BK, Park JY, et al. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. Am J Gastroenterol. 2020; 115: 584-595. PubMed: https://pubmed.ncbi.nlm.nih.gov/32141917/
  15. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020; 111: 154170. PubMed: https://pubmed.ncbi.nlm.nih.gov/32006558/
  16. Targher GBertolini LPadovani R. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30: 1212-1218. PubMed: https://pubmed.ncbi.nlm.nih.gov/17277038/
  17. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999; 91: 1147–1154. PubMed: https://pubmed.ncbi.nlm.nih.gov/10393723/
  18. Lin XF, Shi KQ, You J i sur. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep. 2014; 41: 2989–2997. PubMed: https://pubmed.ncbi.nlm.nih.gov/24449368/
  19. Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation?2018; 87: 10-13. PubMed: https://pubmed.ncbi.nlm.nih.gov/30172755/
  20. Ahn JSSinn DHMin YW. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther.2017; 45: 345-353. PubMed: https://pubmed.ncbi.nlm.nih.gov/27859470/
  21. Drager LF, Togeiro SM, Polotsky VY. Obstructive sleep spnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013; 62: 569-576. PubMed: https://pubmed.ncbi.nlm.nih.gov/23770180/
  22. Resta O, Foschino-Barbaro MP, Legari G, Talamo S, Bonfitto P, et al. Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord. 2001; 25: 669–675. PubMed: https://pubmed.ncbi.nlm.nih.gov/11360149/
  23. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med. 2005; 172: 1590–1595. PubMed: https://pubmed.ncbi.nlm.nih.gov/16192452/
  24. Lee JY, Kim CW, Lee KC, Lee JH, Kang SH, et al. Effect of Intermittent Hypoxia on Metabolic Syndrome and Insulin Resistance in the General Male Population. Medicina (Kaunas). 2021; 57: 668. PubMed: https://pubmed.ncbi.nlm.nih.gov/34209501/
  25. Corey KE, Misdraji J, Gelrud L, King LY, Zheng H, et al. Obstructive sleep apnea is associated with nonalcoholic steatohepatitis and advanced liver histology. Dig Dis Sci. 2015; 60: 2523–2528. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499481/
  26. Vgontzas ANBixler EOChrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev.2005; 9: 211-224. PubMed: https://pubmed.ncbi.nlm.nih.gov/15893251/
  27. Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, et al. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. Sci Rep. 2021; 11: 13473.
  28. Sharma SKAgrawal SDamodaran D. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med.2011; 365: 2277-2286. PubMed: https://pubmed.ncbi.nlm.nih.gov/22168642/
  29. Petroni ML, Brodosi L, Marchignoli F, Sasdelli AS, Caraceni P, et al. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. Nutrients. 2021; 13: 2748.
  30. American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: Standards of medical care in Diabetes-2021. Diabetes Care. 2021; 44: 100–110. PubMed: https://pubmed.ncbi.nlm.nih.gov/33298419/
  31. Silva Figueiredo P, Inada AC, Ribeiro Fernandes M, et al. An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. Molecules. 2018; 23: 877. PubMed: https://pubmed.ncbi.nlm.nih.gov/29641459/
  32. Finicelli M, Squillaro T, Di Cristo F, Di Salle A, Melone MAB, et al. Metabolic syndrome, Mediterranean diet, and polyphenols: Evidence and perspectives. J Cell Physiol. 2019; 234: 5807-5826. PubMed: https://pubmed.ncbi.nlm.nih.gov/30317573/
  33. Ditano-Vázquez P, Torres-Peña JD, Galeano-Valle F, Pérez-Caballero AI, Demelo-Rodríguez P, et al. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. Nutrients. 2019; 11: 2833. PubMed: https://pubmed.ncbi.nlm.nih.gov/31752333/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More